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analysis, showed 89.2% of iterations favored denosumab. CONCLUSIONS: Deno-
sumab was cost-effective over zoledronate from the private health care setting
perspective in Brazil, adding gains in benefits at a lower cost in preventing osteo-
porotic fractures in postmenopausal women.
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OBJECTIVES: To explore the cost-utility of adding tocilizumab (TCZ) monotherapy
to current monotherapy treatment sequences in moderate/severe adult rheuma-
toid arthritis (RA) patients with inadequate response to one or more disease-mod-
ifying antirheumatic drugs (DMARD-IR) and intolerance/contra-indication to
methotrexate (MTX) in Portugal. METHODS: A cost-utility analysis was conducted
with a societal perspective. The analysis considered two scenarios: a treatment
sequence starting with TCZ followed by two tumor necrosis factor inhibitors (anti-
TNF), adalimumab (ADA) and etanercept (ETA) and palliative care (PC) - scenario
1 - or ETA, ADA and PC - scenario 2 - compared to the same treatment sequence
without TCZ. Patients characteristics (age, starting HAQ-DI score and gender) were
based on TCZ randomized clinical trial (RCT) data in monotherapy. ACR response
data for the other biologic treatments were sourced from corresponding published
RCTs in monotherapy. A mapping model was used to assign QALYs to patients
based on HAQ-DI scores and EQ-5D collected in other RCTs (Kremer J, 2008; Smolen
JS, 2008). Resource utilization was estimated based on a Portuguese rheumatolo-
gists= expert panel. Unit costs were obtained from Portuguese official sources. Costs
and QALYs were discounted annually at 5%. Uncertainty around the model key
parameters was explored via probabilistic sensitivity analysis (PSA). RESULTS: The
model estimated that the treatment sequences starting with TCZ result in higher
QALYs and additional costs versus comparator sequences. The incremental cost-
effectiveness ratios (ICER) in both scenarios is below a threshold of 30.000€ per
QALY gained. Sensitivity analysis and PSA showed that results are robust to pa-
rameter changes. CONCLUSIONS: Results of this analysis suggest that TCZ in
monotherapy, added as first line biologic to currently used anti-TNF mono-
therapy sequences, represents an efficacious and cost-effective alternative to
sequences currently used for treating MTX intolerant/contra-indicated RA pa-
tients in Portugal.
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OBJECTIVES: To estimate the cost-effectiveness of TCZ vs. ADA used as mono-
therapy (mono) for RA from the U.S. payer perspective. METHODS: We compared
TCZ (8mg/kg every 4wks) mono vs. two doses of ADA mono: 1) 40mg weekly, 2)
40mg every 2wks. TCZ and ADA every 2wks efficacy was from the ADACTA trial;
ADA weekly efficacy was estimated using data from ADACTA and a 2004 van de
Putte study. For the 6-month trial period, we calculated incremental cost per addi-
tional ACR responder, and low disease activity score (LDAS) achieved for TCZ vs.
ADA. We also used a patient-level simulation model to estimate lifetime incremen-
tal cost per quality-adjusted life year (QALY) of initiating treatment with TCZ vs.
ADA mono; both followed by etanercept-certolizumab-palliative care. Non-re-
sponders discontinue at 6 months; responders experience a constant probability of
discontinuation thereafter. Discontinued patients go to the next treatment in the
sequence. ACR responses are linked to HAQ, which is mapped to utility to estimate
QALYs (Diamantopoulos 2012). Costs include drug treatment, monitoring, and di-
rect medical resource utilization (derived from HAQ; Kobelt 1999). Costs and QALYs
were discounted at 3%. Sensitivity analyses were performed. RESULTS: TCZ
8mg/kg mono had higher ACR responses and QALYs and lower costs compared
with ADA mono 40mg weekly. Compared with ADA 40mg every 2wks, the 6-month
incremental cost for TCZ ranged from $2,077/additional LDAS achiever to $4,509/
additional ACR70 responder; in the lifetime model the ICER was $49,195/QALY. In
one-way sensitivity analyses, results were most sensitive to changes in drug costs
and ACR responses. CONCLUSIONS: TCZ (8mg/kg every 4wks) mono dominates
(more effective and less costly) ADA (40mg weekly) mono and is cost-effective
compared to ADA (40mg every 2wks) mono, from a US payer perspective, in pa-
tients with severe RA for whom methotrexate treatment is not appropriate.
PMS44
COST-EFFECTIVENESS OF ALENDRONATE THERAPY FORCORTICOSTEROID-
INDUCED OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH RHEUMATOID
ARTHRITIS IN JAPAN
Moriwaki K1, Noto S1, Inoue H1, Yanagisawa S2
1Niigata University of Health and Welfare, Niigata, Japan, 2Faculty of Pharmaceutical Sciences,
Himeji Dokkyo University, Himeji, Japan
OBJECTIVES: To estimate the cost-effectiveness of alendronate therapy for corti-
costeroid-induced osteoporosis in postmenopausal women with rheumatoid ar-
thritis in Japan. METHODS: A Markov model with six health states (no fracture,
post-vertebral fracture, post-hip fracture, post-vertebral and hip fracture, bedrid-
den, and death) was developed to predict lifetime costs and quality-adjusted life
years (QALYs) of five years of alendronate therapy versus no anti-osteoporotic
therapy in rheumatoid arthritis patients without fracture history. Fracture risk
associated with age and bone mineral density (BMD) was derived from epidemio-
logic studies in Japan. For the base-case analysis, we ran the model with age of 65
and BMD 70% of the young adult mean (YAM). Probabilistic sensitivity analysis was
performed to assess parameter uncertainty. RESULTS: Compared with no anti-
osteoporotic therapy, alendronate therapy cost an additional US$1,255 per person
and conferred an additional 0.026 QALYs, resulting in an incremental cost-effec-
tiveness ratio (ICER) of US$48,260 per QALY gained in 65-year-old patient with BMD
70% of YAM. In 70- and 75-year-old women, the ICER were estimated to be
US$32,473 and US$20,255 per QALY gained, respectively. Appling a willingness to
pay threshold of $60,000 per QALY, the probability of being cost-effective was es-
timated to 66.2 %, 92.7%, and 99.9% in 65-, 70-, and 75-year-old women with BMD
70% of YAM, respectively. CONCLUSIONS: Anti-osteoporotic therapy for cortico-
steroid-induced osteoporosis in postmenopausal women with rheumatoid arthri-
tis would be cost-effective in terms of Japan health care system.
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OBJECTIVES: There is evidence supporting the effectiveness of both exercise ther-
apy and manual therapy for hip and knee osteoarthritis (OA), but no clinical trials
or economic evaluations have been reported of their use alone or in combination
compared against usual medical care.METHODS:We conducted a cost-utility anal-
ysis alongside a randomized controlled trial. Adults meeting the American College
of Rheumatology criteria for hip or knee OA were randomly allocated to either: a)
exercise therapy; b) manual therapy; c) combined exercise therapy and manual
therapy; or d) usual medical care only. Changes in the Western Ontario and Mc-
Master (WOMAC) osteoarthritis index, physical performance measures, quality ad-
justed life years (QALY), and economic costs (presented in 2009 NZD) were assessed
at 12 months, blind to group allocation. Incremental cost-utility ratios (ICER) with
95% CIs and cost-effectiveness acceptability curves were reported, from both
health care system and societal perspectives. RESULTS: Of 206 participants re-
cruited, 193 (93.2%) were retained at follow-up. Intention-to-treat analysis showed
effect sizes for WOMAC score changes at one year compared with the usual care
group of 0.53 (Cohen’s d; 95% CI .14, .92) for manual therapy alone, 0.32 (-.07, .71) for
exercise therapy alone, and 0.31 (-.09, .70) for combined exercise therapy and man-
ual therapy. QALY gain and physical performance test outcomes significantly fa-
voured the exercise therapy group. Exercise therapy resulted in incremental cost-
utility ratios regarded as cost-effective at a willingness-to-pay threshold of 2x GDP
per-capita, but was not cost saving. Manual therapy was cost saving relative to
usual care from the societal perspective.CONCLUSIONS: Both exercise physiother-
apy and manual physiotherapy, but not combined therapy, provided incremental
benefit over usual care alone at one year follow-up. From the perspective of the
New Zealand health system, exercise therapy was best value, and from the per-
spective of society, manual therapy saved costs.
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OBJECTIVES: The treatment of rheumatoid arthritis (RA) is usually initiated with
disease-modifying anti-rheumatic drugs (DMARDs). In patients who do not tolerate
or respond to DMARDs, treatment with a biologic agent may be considered. This
study aimed to estimate the cost effectiveness of adalimumabmethotrexate
(ADAMTX) relative to standard DMARD therapy for treating early- and late-stage
RA in Italy. METHODS: Separate discrete event simulations were performed to
model the clinical and treatment pathways of early and late RA. Patients’ clinical
course was modeled as a function of baseline characteristics, treatment efficacy,
risks of adverse events, treatment withdrawals, and death. Treatment efficacy was
based on American College of Rheumatology (ACR) response, which was translated
into Health Assessment Questionnaire (HAQ) scores to facilitate the assignment of
costs and utilities. Survival, quality-adjusted life years (QALYs), and direct medical
costs were estimated over a lifetime. Inputs of demographics, treatment efficacy,
the ACR-HAQ relationship, and utility scores were extracted from several
ADAMTX trials; risks of adverse events, withdrawal rates, prices, and resource
use from the literature; and life expectancy from Italian life tables. Assumptions
regarding resource use and HAQ progression were consistent with published RA
models. RESULTS: For early RA, the incremental cost-utility ratio (ICUR) for
ADAMTX over DMARDs-only treatment (after failing two doses of MTX and fol-
lowed by rescue therapy) was estimated to be €15,770/QALY (3.37 QALYs gained
and €53,100 incremental costs). For late-stage RA, the ICUR for ADAMTX relative
to DMARDs only (after failing three doses of MTX and followed by rescue therapy)
was estimated to be €20,129/QALY (1.84 QALYs gained, €37,081 incremental costs).
Sensitivity analyses indicated that ADAMTX was cost effective over a range of key
parameters. CONCLUSIONS: The results of these simulations indicate that treat-
ment of early and late RA with ADAMTX is cost effective relative to DMARDs-only
treatment in an Italian setting.
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